 |
|
Safety and Efficacy of Meloxicam in the Treatment of Osteoarthritis
A 12-Week, Double-blind, Multiple-Dose, Placebo-Controlled Trial
David Yocum, MD;
Roy Fleischmann, MD;
Paul Dalgin, MD;
Jacques Caldwell, MD;
David Hall, PhD;
Paul Roszko, RPh;
for the Meloxicam Osteoarthritis Investigators
Arch Intern Med. 2000;160:2947-2954.
Background Meloxicam (Mobic; Boehringer Ingelheim, Ridgefield, Conn) is an enolic acid derivative of the oxicam group of nonsteroidal anti-inflammatory drugs (NSAIDs) whose mechanism of action may be related to prostaglandin (cyclooxygenase) synthetase inhibition. In previous studies, meloxicam has been found to be safe and effective in the treatment of osteoarthritis (OA) at doses of 7.5 to 15 mg daily. To evaluate a lower dose and a different patient population, we evaluated the efficacy and safety of 3 doses of meloxicam vs placebo and diclofenac for the treatment of OA among patients with symptom exacerbations.
Methods In this double-blind, double-dummy, parallel-group, multicenter study, 774 patients with confirmed OA of the hip or knee and a flare were randomized and treated with daily oral administration of meloxicam tablets (at dosages of 3.75, 7.5, or 15 mg/d), diclofenac (100 mg [50 mg twice daily]), or placebo. Treatment was for 12 weeks, with regular assessments for drug safety and efficacy. Safety was assessed by evaluation of adverse events, vital signs, and laboratory data. Primary efficacy variables included the Western Ontario and McMaster University Osteoarthritis (WOMAC) index, the patient's overall assessment of pain, and the patient's and investigator's overall assessment of disease activity.
Results The incidence of all adverse events was lower at each dosage of meloxicam than for diclofenac but greater than for placebo. However, the incidence of gastrointestinal adverse events and dropout rates because of such events was the same for meloxicam as for placebo and lower than for diclofenac. Meloxicam, at 7.5 and 15 mg/d, and diclofenac were statistically significantly more effective than placebo for all end points, while the 3.75-mg/d dosage of meloxicam did not always reach statistical significance for all end points. Efficacy was evident after 2 weeks of treatment, improved with increasing doses, and was maintained until the end of the trial.
Conclusions Meloxicam is a safe and effective medication for the symptomatic treatment of OA. The data support consideration of 7.5 to 15 mg of meloxicam once daily to treat the pain and stiffness of OA, with gastrointestinal tolerability comparable to that of placebo.
From the Arizona Arthritis Center, University of Arizona, Tucson (Dr Yocum); Rheumatology Associates, Dallas, Tex (Dr Fleischmann), Arthritis and Allergy Institute, Daytona Beach, Fla (Dr Caldwell); and Boehringer Ingelheim, Ridgefield, Conn (Dr Hall and Mr Roszko).
Dr Dalgin is deceased. Dr Dalgin was in a private practice in Stamford, Conn.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs
Rabenda et al.
Ann Rheum Dis 2005;64:688-693.
ABSTRACT
| FULL TEXT
Efficacy and Safety of a Topical Diclofenac Solution (Pennsaid) in the Treatment of Primary Osteoarthritis of the Knee: A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Roth and Shainhouse
Arch Intern Med 2004;164:2017-2023.
ABSTRACT
| FULL TEXT
Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial
Bookman et al.
CMAJ 2004;171:333-338.
ABSTRACT
| FULL TEXT
Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers
van Ryn et al.
J Clin Pharmacol 2004;44:777-784.
ABSTRACT
| FULL TEXT
Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach
Richy et al.
Ann Rheum Dis 2004;63:759-766.
ABSTRACT
| FULL TEXT
Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs
MacDonald et al.
Gut 2003;52:1265-1270.
ABSTRACT
| FULL TEXT
Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population
Smith and Baird
AM J HOSP PALLIAT CARE 2003;20:297-306.
ABSTRACT
|
